Use of risk stratification to guide ambulatory management of neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee

Intern Med J. 2011 Jan;41(1b):82-9. doi: 10.1111/j.1445-5994.2010.02339.x.

Abstract

Utilization of risk-stratification tools in the setting of neutropenic fever is currently limited by inadequate knowledge and lack of awareness. Within this context, the approach to management of low-risk patients with neutropenic fever is inconsistent with the available evidence across many Australian treating centres. These clinical guidelines define and clarify an accepted standard of care for this patient group given the current evidence base. The Multinational Association for Supportive Care in Cancer risk index is presented as the preferred risk assessment tool for determining patient risk. Suitability of ambulatory care within specific patient populations is discussed, with defined eligibility criteria provided to guide clinical decision-making. Detailed recommendations for implementing appropriate ambulatory strategies, such as early discharge and outpatient antibiotic therapy, are also provided. Due consideration is given to infrastructural requirements and other supportive measures at a resourcing and operational level. An analysis of the relevant health economics is also presented.

Publication types

  • Practice Guideline
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Ambulatory Care / methods*
  • Ambulatory Care / organization & administration
  • Anti-Bacterial Agents / therapeutic use
  • Australia
  • Cancer Care Facilities / organization & administration
  • Cancer Care Facilities / standards
  • Disease Management*
  • Drug Resistance, Multiple, Bacterial
  • Evidence-Based Medicine
  • Fever / drug therapy*
  • Fever / etiology
  • Humans
  • Neoplasms / complications*
  • Neutropenia / complications*
  • Patient Care Team
  • Patient Discharge
  • Practice Patterns, Physicians'
  • Recurrence
  • Risk
  • Risk Management*
  • Severity of Illness Index*

Substances

  • Anti-Bacterial Agents